Latest Investigation News

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

CZR Resources has launched a new drilling campaign at its Croydon Gold Project, focusing on extending known mineralisation and testing for high-grade ore shoots and Hemi-style intrusions. The program leverages recent geological insights and a robust $67 million cash position.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Australian Mines Limited's latest scoping study for its Flemington Scandium Project reveals strong financial metrics and significant upside potential tied to scandium pricing, underscoring the project's strategic position in critical minerals.

Venari Minerals has achieved a key metallurgical milestone by producing 99.5% pure battery-grade lithium carbonate from its Red Mountain Project in Nevada, highlighting its potential as a domestic US lithium chemical source alongside valuable by-products.

European Resources has more than doubled its Korsnäs rare earth resource following a successful drilling program and metallurgical advances, underpinning a $3.4 million capital raise to fund further development.

Galan Lithium has completed Phase 1 construction at Hombre Muerto West, secured A$40 million to expand production capacity by 30%, and is poised to begin lithium chloride concentrate shipments in H2 2026.

Antipa Minerals completed its CY2025 drilling program at the Minyari Gold-Copper Project, revealing new high-grade zones and boosting its Mineral Resource Estimate to 3.6 million ounces gold equivalent. The company is progressing its Pre-Feasibility Study and has commenced a major new drilling campaign, supported by a strong cash position.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.

Generation Development Group’s subsidiary Generation Life Limited has swiftly contained a cyber incident involving unauthorised access through a third-party provider, with no evidence of impact on core systems or unauthorised transactions.

Alliance Nickel is pursuing capital cost savings at its NiWest Nickel-Cobalt Project through vat leaching trials while reporting promising gold assay results from initial drilling at Australia United. A $4.15 million entitlement offer aims to fund these efforts amid ongoing offtake renegotiations with Stellantis.